Table 1.
patients’ clinical characteristics of the training and validation groups.
| Training Group | Validation Group | p –value | |
|---|---|---|---|
| Demographic Characteristics | |||
| age, years (mean; median; range) | 61; 61; 20–86 | 65; 66; 18–95 | 0.0004 |
| sex (Male; Female) | 123; 43 | 57; 28 | 0.8434 |
| weight (mean; median; range) | 79; 80; 45–124 | 75; 75; 39–120 | 0.0099 |
| height (mean; median; range) | 170; 170; 150–190 | 169; 170; 142–187 | 0.0170 |
| BMI (mean; median; range) | 27; 27, 18–43 | 26; 26; 18–47 | 0.0097 |
| race (Caucasian; Hispanic; Asiatic; Afro-american) | 138; 12; 2; 1 | 81; 2; 1; 1 | 0.9990 |
| Comorbidities | |||
| Arterial hypertension (y; n, missing) | 67; 82; 17 | 40; 42; 3 | 0.0350 |
| Coronary disease (y; n, missing) | 12; 137; 17 | 15; 67; 3 | 0.2666 |
| Diabetes mellitus (y; n, missing) | 43; 126; 17 | 15; 67; 3 | 0.0980 |
| Obstructive pulmonary disease (y; n, missing) | 4; 166; 17 | 10; 73; 3 | 0.0021 |
| Chronic renal disease (y; n, missing) | 12; 137; 17 | 11; 71; 3 | 0.4080 |
| Active Cancer (y; n, missing) | 10; 140; 16 | 9; 74; 2 | 0.3489 |
| ICU (y; n, missing) | 37; 99; 30 | 12; 71; 2 | 0.4260 |
| Biological drugs (y; n; missing) | 55; 97; 14 | 78; 7; 0; 0 | 0.0415 |
| satO2 (mean; median; range) | 91; 93; 50–100 | 93; 95; 63–100 | 0.0025 |
| FiO2 (mean; median; range) | 1; 1; 1–1 | 0.27; 0.21; 0.21–1 | 0.1654 |
| satO2/FiO2 (mean; median; range) | 408; 438; 70–476 | 409; 447; 93–476 | 0.0126 |
| EGAPaO2 (mean; median; range) | 66; 63; 28–251 | 68; 66; 37–127 | 0.2512 |
| EGAFiO2 (mean; median; range) | 0.32; 0.21; 0.21–1.00 | 0.3; 0.21; 0.21–1 | 0.0065 |
| PaO2/FiO2 (mean; median; range) | 262; 281; 47–667 | 283; 300; 58–586 | 0.1301 |
| Body temperature (mean; median; range) | 38; 38; 36–41 | 38; 38; 36–41 | 0.0222 |
| Laboratory results | |||
| Hemoglobin (mean; median; range) | 14; 14; 7–51 | 13; 14; 8–18 | 0.1067 |
| Absolute lymphoncytes (mean; median; range) | 1.27; 0.90; 0.30–42.00 | 1.14; 1.10; 0.10–5.70 | 0.8592 |
| Glycemia (mean; median; range) | 131; 109; 58–500 | 117; 104; 71–305 | 0.5807 |
| Aspartate transaminase (mean; median; range) | 58; 46; 13–378 | 54; 39; 13–225 | 0.5626 |
| Alanine transaminase (mean; median; range) | 52; 37; 8–578 | 48; 28; 11–275 | 0.7346 |
| Lactate deidrogenase (mean; median; range) | 427;409; 115–1101 | 392; 320; 128–2017 | 0.3303 |
| C-reactive protein (mean; median; range) | 113; 91; 3–410 | 82; 66; 0–313 | 0.0925 |
| Creatinine (mean; median; range) | 1.08; 1.03; 0.44–5.71 | 1.18; 0.98; 0.56–7.57 | 0.8038 |
| Endpoints | |||
| Deaths (y; n) | 25; 141 | 18; 85 | 0.9900 |